Document Information [Line Items]
Document type
Amendment flag
Document period end date
Amendment description
Entity common stock shares outstanding
Entity Listings [Line Items]
Entity Listings, Instrument [Axis]
Instrument [Domain]
Entity Listings [Table]
Entity [Text Block]
Entities [Table]
Entity Information [Line Items]
Entity registrant name
Entity central index key
Current fiscal year end date
Entity well known seasoned issuer
Entity voluntary filers
Entity current reporting status
Entity filer category
Entity public float
Income Statement [Abstract]
Statement [Table]
Statement Scenario [Axis]
Statement [Line Items]
Statement of Financial Position [Abstract]
Statement of Cash Flows [Abstract]
Basis of Presentation [Abstract]
Adoption of New Accounting Policies [Abstract]
Financial Instruments [Abstract]
Inventories [Abstract]
Goodwill and Other Intangible Assets [Abstract]
Earnings Per Share Attributable to Common Shareholders [Abstract]
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest [Abstract]
Income (Loss) from Continuing Operations, Including Portion Attributable to Noncontrolling Interest [Abstract]
Costs and expenses:
Revenues Abstract
Cost of sales
Restructuring charges and acquisition related costs
Other Income Expense Net
Selling, informational and administrative expenses
Research and development expenses
Amortization of intangible assets
Acquisition-related in-process research and development charges
Less: Net income attributable to noncontrolling interests
Net income attributable to Pfizer Inc.
Net income before allocation to noncontrolling interests
Discontinued operations - net of tax, total
Income from continuing operations
Provision for taxes on income
Earnings Per Share [Abstract]
Earnings per share - diluted:
Earnings per share - basic:
Earnings Per Share Other Disclosures [Abstract]
Diluted (in shares)
Basic (in shares)
Cash dividends paid per common share (in dollars per share)
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)
Discontinued operations - net of tax (in dollars per share)
EPS Basic
Net income attributable to Pfizer Inc. common shareholders [Diluted]
Discontinued operations - net of tax [Diluted]
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)
Basis of Presentation [Text Block]
Adoption of New Accounting Policies [Text Block]
Comprehensive Income (Expense) [Text Block]
Inventories [Text Block]
Goodwill and Other Intangible Assets [Text Block]
Pension and Postretirement Benefit Plans [Text Block]
Earnings Per Share Attributable to Common Shareholders [Text Block]
Segment Information [Text Block]
Assets
Liabilities and Shareholders' Equity
Total liabilities and shareholders' equity
Liabilities [Abstract]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]
Total assets
Total liabilities
Inventories
Short-term loans
Accounts receivable, less allowance for doubtful accounts
Short-term investments
Cash and cash equivalents
Total current assets
Long-term investments and loans
Property, plant and equipment, less accumulated depreciation
Goodwill
Total identifiable intangible assets, less accumulated amortization
Short-term borrowings, including current portion of long-term debt
Accounts payable
Dividends payable
Income taxes payable
Accrued compensation and related items
Total current liabilities
Long-term debt
Pension benefit obligations
Postretirement benefit obligations
Noncurrent deferred tax liabilities
Other noncurrent liabilities
Total Pfizer Inc shareholders' equity
Common stock
Additional paid-in capital
Employee benefit trust, at fair value
Treasury stock
Retained earnings
Accumulated other comprehensive (loss)/income
Preferred stock
Equity attributable to noncontrolling interests
Total shareholders' equity
Cash and Cash Equivalents, Period Increase (Decrease) [Abstract]
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Revenues
This element represents (i) the total amount of other operating income, not previously categorized, from items that are associated with the entity's normal revenue producing operation; and (ii) recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales, as well as excludes research and development expenses and selling, informational and administrative expenses.
Income from continuing operations before provision for taxes on income
Assets held for sale
Acquisition of Wyeth [Text Block]
Financial Instruments Disclosure [Text Block]
Income taxes
Interest
Supplemental Cash Flow Information:
Net decrease in cash and cash equivalents
Operating Activities:
Investing Activities:
Financing Activities:
Adjustments To Reconcile Net Income Loss Before Allocation To Noncontrolling Interests To Net Cash Provided By Used In Operating Activities Abstract
Share-based compensation expense
Depreciation and amortization
Deferred taxes from continuing operations
Other non-cash adjustments
Net cash provided by operating activities
Purchases of property, plant and equipment
Purchases of short-term investments
Purchases of long-term investments
Other investing activities
Net cash used in investing activities
Proceeds From Issuances Of Short Term Debt Net Of Proceeds From Repayments Of Short Term Debt Maturing In Three Months Or Less
The cash inflow from a borrowing having initial term of repayment of more than three months but less than one year or one operating cycle (if the normal cycle is more than one year) and may include the cash inflow from a borrowing having initial term of repayment within three months net of the cash outflow from repayment of a borrowing having initial term of repayment within three months.
Proceeds from issuances of long-term debt
Principal payments on long-term debt
Cash dividends paid
Net cash (used in)/provided by financing activities
Effect of exchange-rate changes on cash and cash equivalents
Income from continuing operations attributable to Pfizer Inc. common shareholders [Dilluted]
Discontinued operations - net of tax (in dollars per share)
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)
Treasury stock
Accumulated other comprehensive expense
Purchases of property, plant and equipment
Purchases of short-term investments
Purchases of long-term investments
Other investing activities
Increase in short-term borrowings, net
Principal payments on long-term debt
Cash dividends paid
Other taxes payable
Repayments Of Short Term Debt Maturing In More Than Three Months Net Of Repayments Of Short Term Debt Maturing In Three Months Or Less
Principal payments on short-term borrowings
Changes in assets and liabilities, net of acquisitions and divestitures
The cash outflow from a repayment of a borrowing having initial term of repayment of more than three months but less than one year or one operating cycle (if the normal cycle is more than one year) and may include the cash outflow from a repayment of a borrowing having initial term of repayment within three months net of the cash inflow of a borrowing having initial term of repayment within three months.
Proceeds From Sale And Maturity Of Long Term Marketable Securities
Discontinued operations - net of tax
The cash inflow associated with the aggregate amount received by the entity through sale or maturity of short term marketable securities (trading, held-to-maturity, or available-for-sale) during the period.
The cash inflow associated with the aggregate amount received by the entity through sale or maturity of long-term marketable securities (trading, held-to-maturity, or available-for-sale) during the period.
This element represents the complete disclosure related to financial instruments, which may include i) selected financial assets and liabilities; ii) investments in debt and equity securities; iii) short-term borrowings; iv) long-term debt; v) derivative financial instruments and hedging activities; vi) credit risk; and vii) other disclosures related to financial instruments.
This element represents (i) restructuring charges, which are amounts charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a program that is planned and controlled by management, and materially changes either the scope of a business undertaken by an entity, or the manner in which that business is conducted; and (ii) acquisition-related costs, which are costs incurred to effect a business combination which costs have been expensed during the period. Such costs can include transaction costs such as banking, legal, accounting and other costs directly related to effect a business combination as well as external, incremental costs of integration planning that are directly related to a business combination, including costs associated with preparing for systems and other integration activities.
Income from continuing operations before provision for taxes on income
Income from continuing operations
Net income before allocation to noncontrolling interests
Net income attributable to Pfizer Inc.
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)
Total current assets
Total assets
Total current liabilities
Total liabilities
Total Pfizer Inc. shareholders' equity
Total shareholders' equity
Total liabilities and shareholders' equity
Net cash (used in)/provided by operating activities
Net cash provided by/(used in) investing activities
Net cash (used in)/provided by financing activities
Employee benefit trusts
Other financing activities
Changes in assets and liabilities, net of acquisitions and divestitures
Document fiscal year focus
Document fiscal period focus
Document Information [Table]
Legal Entity [Axis]
Entity [Domain]
Parent Company [Member]
Restructuring charges and certain acquisition-related costs
Current Deferred Tax Assets And Other Assets Current
This element represents (i) carrying amount as of the balance sheet date of payments made in advance for income and other taxes, which will be charged against earnings within one year or the normal operating cycle, if longer as well as the current portion of the aggregate tax effects as of the balance sheet date of all future tax deductions arising from temporary differences between tax basis and generally accepted accounting principles basis recognition of assets, liabilities, revenues and expenses, which can only be deducted for tax purposes when permitted under enacted tax laws; after deducting the allocated valuation allowance, if any, to reduce such amount to net realizable value; and (ii) aggregate carrying amount, as of the balance sheet date, of current assets not separately presented elsewhere in the balance sheet.
Current deferred tax assets and other current assets
Non Current Deferred Tax Assets And Other Assets Noncurrent
This element represents (i)the noncurrent portion as of the balance sheet date of the aggregate carrying amount of all future tax deductions arising from temporary differences between tax basis and generally accepted accounting principles basis recognition of assets, liabilities, revenues and expenses, which can only be deducted for tax purposes when permitted under enacted tax laws; after the valuation allowance, if any, to reduce such amount to net realizable value. Deferred tax liabilities and assets shall be classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A deferred tax liability or asset that is not related to an asset or liability for financial reporting, including deferred tax assets related to carryforwards, shall be classified according to the expected reversal date of the temporary difference; and (ii) the aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet due to materiality considerations. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).
Noncurrent deferred tax assets and other noncurrent assets
Proceeds From Sale And Maturity Of Short Term Marketable Securities
Proceeds from sales and redemptions of short-term investments
Proceeds from redemptions and sales of short-term investments
Proceeds from redemptions and sales of long-term investments
Current deferred tax liabilities and other current liabilities
This element represents (i) the current portion of deferred tax liabilities, which result from applying the applicable tax rate to net taxable temporary differences pertaining to each jurisdiction to which the entity is obligated to pay income tax. A current taxable temporary difference is a difference between the tax basis and the carrying amount of a current asset or liability in the financial statements prepared in accordance with generally accepted accounting principles. In a classified statement of financial position, an enterprise shall separate deferred tax liabilities and assets into a current amount and a noncurrent amount. Deferred tax liabilities and assets shall be classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A deferred tax liability or asset that is not related to an asset or liability for financial reporting, including deferred tax assets related to carryforwards, shall be classified according to the expected reversal date of the temporary difference; and (ii) the aggregate carrying amount, as of the balance sheet date, of current obligations not separately disclosed in the balance sheet due to materiality considerations. Current liabilities are expected to be paid within one year (or the normal operating cycle, if longer).
Acquisition of Wyeth [Abstract]
Cost Reduction Initiatives and Acquisition Related Costs [Abstract]
Cost Reduction Initiatives And Acquisition Related Costs Disclosure [Text Block]
Cost-Reduction Initiatives and Acquistion-Related Costs [Text Block]
Pension and Postretirement Benefit Plans [Abstract]
Adjustments to reconcile net income before allocation to noncontrolling interests to net cash (used in)/provided by operating activities:
Weighted-average shares used to calculate earnings per common share:
Financial Instruments [Text Block]
Other deductions - net
Increase in short-term borrowings
Supplemental Cash Flow Information Cash Paid During Period For [Abstract]
Supplemental Cash Flow Information - Cash paid during the period for:
Comprehensive Income/(Loss) [Text Block]
Taxes on Income [Abstract]
Taxes on Income [Text Block]
Net (decrease)/increase in cash and cash equivalents
Description of cost-reduction initiatives associated with a comprehensive plan to integrate acquired operations, generate cost savings and capture synergies across the company; as well as costs incurred in connection with an acquisition. These costs include (i) restructuring activities, including exit and disposal activities, the major types of costs associated with the plan activities and the accrual balance at the end of the period; (ii) integration costs, which represent external, incremental costs directly related to integrating acquired businesses; (iii) implementation costs, which represent external, incremental costs directly related to implementing cost-reduction initiatives prior to the Wyeth acquisition and primarily include expenditures related to system and process standardization and the expansion of shared services; (iv) additional depreciation-asset restructuring, which represents the impact of changes in the estimated useful lives of assets involved in restructuring actions; and (v) transaction costs, representing external costs incurred in connection with an acquisition.
Comprehensive Income (Loss) [Abstract]
Schedule Of Recognized Identifiable Assets Acquired And Liabilities Assumed As Part Of Business Combination [Text Block]
Schedule of acquired assets and liabilities assumed as of the acquisition date, including measurement period adjustments.
Schedule of Business Acquisition [Table]
Wyeth Acquisition Purchase Price
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Working Capital Excluding Inventories
Working capital, excluding inventories
InventoriesAcquisition
Property, plant and equipment
In-process research and development
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed In Process Research And Development
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Noncurrent Assets
Other noncurrent assets
The amount of other noncurrent assets recognized as of the acquisition date.
The amount of in process research and development recognized as of the acquisition date.
The amount of working capital, excluding inventories, recognized as of the acquisition date.
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Benefit Obligations
Benefit obligations
The amount of benefit obligations recognized as of the acquisition date.
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net Tax Accounts
Net tax accounts
The amount of net tax accounts recognized as of the acquisition date.
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Noncurrent Liabilities
Other noncurrent liabilities
The amount of other noncurrent liabilities recognized as of the acquisition date.
Total identifiable net assets
Total identifiable net assets
Net assets acquired
Net assets acquired
Less: Amounts attributable to noncontrolling interests
Total consideration transferred
Total consideration transferred
Inventories
Schedule of restructuring charges [Text Block]
Schedule of costs in connection with cost-reduction initiatives and the acquisition of Wyeth.
Cost Reduction Initiatives and Acquisition Related Costs [Table]
Cost reduction initiatives and acquisition costs [Line Items]
Business Combination Acquisition Related Costs Integration Costs
Integration costs
Integration costs represent external, incremental costs directly related to integrating Wyeth and primarily include expenditures for consulting and systems integration.
Restructuring charges
Additional Depreciation Asset Restructuring
Additional depreciation-asset restructuring
Additional depreciation asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
Implementation Costs
Implementation costs
Implementation costs represent external, incremental costs directly related to Implementing cost-reduction initiatives prior to Pfizer's acquisition of Wyeth, and primarily include expenditures related to system and process standardization and the expansion of shared services.
Cost Reduction Initiatives And Acquisition Costs
Total costs incurred in connection with Pfizer's cost-reduction initiatives and the acquisition of Wyeth.
Cost Reduction Initiatives and Acquisition Costs of Wyeth [Abstract]
Total
Footnote information [Abstract]
Senior unsecured notes
Asset impairments [Member]
Other Restructuring Charges [Member]
Employee Severance [Member]
Other [Member]
Costs Incurred
Activity
Accrual
Restructuring charges footnote information [Abstract]
Restructuring Charges [Member]
Restructuring charges abstract
Estimated Employee Terminations
Actual Employees Terminated
Recording of Assets Acquired and Liabilities Assumed
Business Acquisition Purchase Price
Additional depreciation asset restructuring and implementation costs [Abstract]
Asset depreciation asset restructuring [Member]
Total
Restructuring and related costs by type [Axis]
Types of restructuring [Domain]
Schedule Of Available For Sale And Held To Maturity Debt Maturities [Text Block]
Contractual maturities of available-for-sale and held-to-maturity debt securities [Text Block]
Schedule of contractual maturities of the available for sale and held to maturity debt securities.
This element represents the disclosure related to certain financial assets and liabilities, including financial assets and liabilities measured at fair value on a recurring basis.
Schedule of gains (losses) on interest rate risk [Text Block]
Financial Instruments [Line Items]
Financial assets measured at fair value on a recurring basis
Financial liabilities measured at fair value on a recurring basis
Available - for - sale debt securities [Member]
Trading securities [Member]
Available - for - sale money market funds [Member]
Available - for - sale equity securities, excluding money market funds [Member]
Foreign currency swaps [Member]
Interest rate swaps [Member]
Foreign currency forward-exchange contracts [Member]
Fair Value Assets Measured on Recurring Basis [Domain]
Fair Value Assets Measured on Recurring Basis Disclosure Items [Axis]
Fair Value Assets Measured on Recurring Basis Disclosure Items [Domain]
Fair Value Liabilities Measured on Recurring Basis Disclosure Items [Axis]
Fair Value Liabilities Measured on Recurring Basis Disclosure Items [Domain]
Other selected financial assets [Abstract]
Other Selected Financial Assets
Total
Other financial liabilities [Abstract]
Other Financial Liabilities
Total
Fair Value Measurements [Table]
Financial Liabilities Measured At Fair Value On Recurring Basis [Abstract]
Footnotes to selected financial assets and liabilities [Abstract]
Money market funds held in escrow
Selected financial assets and liabilities presented in the condensed consolidated balance sheets [Line Items]
Cash and cash equivalents at fair value
Fair value inputs Level 1 [Member]
Selected Financial Liabilities Current Deferred Tax Liabilities And Other Current Liabilities
Current deferred tax liabilities and other current liabilities
Selected financial liabilities presented in the balance sheet caption, Current deferred tax liabilities and other current liabilities, at the balance sheet date.
Selected Financial Liabilities Other Noncurrent Liabilities
Other noncurrent liabilities
Selected financial liabilities presented in the balance sheet caption, Other Noncurrent liabilities, at the balance sheet date.
Footnotes to selected financial assets and liabilities presented in consolidated balance sheets [Abstract]
Fair Value By Balance Sheet Grouping [Axis]
Fair Value Disclosure Items [Domain]
Investments in Debt and Equity Securities [Abstract]
Debt Securities
This item represents the total of all debt securities grouped by maturity dates.
Total debt securities
Available For Sale Securities Equity Securities Money Market Funds
Available - for - sale money market funds
This item represents equity securities categorized neither as held-to-maturity nor trading. Money market funds represent ownership in debt instruments. If money markets funds are determined to have had an other than temporary decline in fair value below its amortized cost basis the loss loss shall be recognized in earnings.
Available - for - sale securities equity securities excluding money market funds
Available - for - sale equity securities, excluding money market funds
This item represents equity securities excluding money market funds categorized neither as held-to-maturity nor trading. Equity securities excluding money market funds represent ownership interests or the right to acquire ownership interests in corporations and other legal entities which ownership interest is represented by shares of common or preferred stock (which is not mandatorily redeemable or redeemable at the option of the holder), convertible securities, stock rights, or stock warrants. Unrealized gains and losses related to Available-for-sale Securities are excluded from earnings and reported in a separate component of shareholders' equity (other comprehensive income), unless the Available-for-sale Security is designated as a hedge or is determined to have had an other than temporary decline in fair value below its amortized cost basis. All or a portion of the unrealized holding gain or loss of an Available-for-sale Security that is designated as being hedged in a fair value hedge shall be recognized in earnings during the period of the hedge, as should other than temporary declines in fair value below costs basis.
Schedule of available - for - sale securities [Axis]
Major Types of Debt and Equity Securities [Domain]
Securities (Assets) [Member]
Debt Securities [Member]
Western European and other government debt [Member]
Western European and other government agency debt [Member]
Supranational debt [Member]
Represents the debt of international organizations such as the World Bank, the International Monetary Fund, regional multilateral development banks, multilateral financial institutions, and other similar organizations.
Certificates of deposit [Member]
Corporate debt [Member]
Federal Home Loan Mortgage Corporation and Federal National Mortgage Association asset backed securities [Member]
This category includes investments in asset-backed debt securities issued by the Federal Home Loan Mortgage Corporation and Federal National Mortgage Association.
Reverse repurchase agreements [Member]
Schedule of held - to - maturity debt securities [Axis]
Major Types of Debt Securities [Domain]
Certificates of deposit and other [Member]
This category includes information about certificates of deposit and other held to maturity debt securities not separately identified.
Short - Term Borrowings [Abstract]
Commercial paper
Long - Term Debt [Abstract]
Senior unsecured notes at fair value
Derivative Financial Instruments and Hedging Activities
Cash and cash equivalents
Senior unsecured notes
Major Types of Debt Securities [Domain]
Foreign currency debt used as hedging instrument [Member]
Foreign currency borrowings used as hedging instruments [Member]
Available - for - sale debt securities
Held - to - maturity debt securities
Available - for - sale debt securities maturities within 1 year
Available - for - sale debt securities maturities over 1 to 5 years
Available - for - sale debt securities maturities total
Long-term loans, carried at cost
Debt securities maturities over 1 to 5 years
Short - term borrowings
Commercial Paper [Member]
Credit Risk
Guarantee [Abstract]
Guarantee for Wyeth's obligation
Collateral received
Schedule Of Components Of Comprehensive Income (Loss) [Text Block]
Schedule of components of comprehensive income (loss).
Other comprehensive income/(loss):
Net unrealized losses on derivative financial instruments
Net unrealized gains/(losses) on available - for - sale securities
Benefit plan adjustments
Total comprehensive (loss) income before allocation to noncontrolling interests
Less: Comprehensive income attributable to noncontrolling interests
Comprehensive (loss) income attributable to Pfizer Inc.
Total comprehensive income/(loss) before allocation to noncontrolling interests
Comprehensive income/(loss) attributable to Pfizer Inc.
Schedule Of Components Of Inventories [Text Block]
Total inventories
Finished goods
Work - in - process
Raw materials and supplies
Schedule of changes in carrying amount of goodwill [Text Block]
Goodwill By Segment [Axis]
Goodwill, Segment [Domain]
Biopharmaceutical [Member]
Diversified [Member]
Changes in the carrying amount of goodwill
Balance, December 31, 2009
Goodwill Other Adjustments
Reflects net changes to the recorded value of goodwill not separately disclosed, primarily for foreign currency translation adjustments.
Text block covering the Disclosure of the details of finite-lived and indefinite-lived intangible assets, excluding goodwill, in total and by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.
Other
Balance, July 4, 2010
Measurement Period Adjustments Abstract
Measurement Period Adjustment Inventory
Inventories
Measurement Period Adj PPE
Property, plant and equipment
Business Combination Provisional Information Initial Accounting Incomplete Adjustment Inprocess Research And Development
In - process research and development
This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to net tax accounts in connection with a business combination for which the initial accounting was incomplete.
This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to in-process research and development acquired in connection with a business combination for which the initial accounting was incomplete.
Business Combination Provisional Information Initial Accounting Incomplete Adjustment Net Tax Accounts
Net tax accounts
Business Combination Provisional Information Initial Accounting Incomplete Adjustment In Goodwill
Goodwill
This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to goodwill acquired in connection with a business combination for which the initial accounting was incomplete.
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed In Goodwill
Goodwill
Business Combination Provisional Information Initial Accounting Incomplete Adjustment Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net
Total identifiable net assets
Business Combination Provisional Information Initial Accounting Incomplete Adjustment Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net
Net assets acquired
Finite-Lived Intangible Assets by Major Class [Axis]
Developed technology rights [Member]
Finite-Lived Intangible Assets, Major Class Name [Domain]
Licensing Agreements [Member]
Trademarks [Member]
Brands [Member]
Finite-lived intangible assets
Finite lived intangible assets gross carrying amount
Gross Carrying Amount
Finite lived intangible assets accumulated amortization
Accumulated Amortization
Finite lived intangible assets net
Identifiable Intangible Assets, less Accumulated Amortization
Other intangible assets [Member]
Other [Member]
Indefinite-lived Intangible Assets By Major Class [Axis]
Indefinite-lived Intangible Assets, Major Class [Domain]
Indefinite-lived intangible assets
Indefinite-lived intangible assets excluding goodwill
Indefinite - lived brands
Indefinite - lived In-process research and development
Indefinite-lived trademarks
Carrying amount as of the balance sheet date for in-process research and development. In-process research and development assets that have not yet received regulatory approval and are required to be classified as indefinite- lived assets until the successful completion or the abandonment of the associated research and development effort. During the development period after acquisition, these assets will not be amortized until approval is obtained.
Carrying amount as of the balance sheet date for brands. Brands represent the amortized or unamortized cost associated with tradenames and know-how, as the products themselves no longer receive patent protection.
The rights acquired through registration of a brand name to gain or protect exclusive use thereof.
Other intangibles not otherwise specified in the taxonomy.
Goodwill and Other Intangible Assets Narrative [Abstract]
Amortization expense for finite-lived intangible assets
Aggregate notional amount of interest rate derivative financial instruments
Derivatibe Instruments, Gain (Loss) by Hedging Relationship [Axis]
Hedging Relationship [Domain]
Fair Value Hedging [Member]
Cash Flow Hedging [Member]
Net Investment Hedging [Member]
Nondesignated [Member]
Gains losses incurred to hedge or offset operational foreign exchange or interest rate risk [Abstract]
Recognized in OID
Recognized in OCI
Reclassified from OCI to OID
Derivative Instruments Gain (Loss) by Derivative Instrument Risk [Axis]
Foreign currency short - term borrowings [Member]
Foreign currency long - term debt [Member]
Derivative Contract Type [Domain]
Non - Derivative Financial Instruments in Net Investment Hedge Relationships [Abstract]
Schedule of net periodic benefit costs of pension and post retirement benefit plans [Text Block]
Financial Instruments Narrative [Abstract]
Posted collateral
Additional collateral
Selected Financial Assets
Selected Financial Liabilities
Financial Assets Measured At Fair Value On Recurring Basis [Abstract]
Segment Information [Abstract]
Business Acquisition [Table]
United States Supplemental Non Qualified Pension Plans Of U S Entity Defined Benefit [Member]
U.S. Qualified [Member]
International [Member]
U.S. Supplemental (Non-Qualified) [Member]
Defined Benefit Plans Disclosures Defined Benefit Plans [Axis]
Defined Benefit Plans [Domain]
Pension Plans Defined Benefit [Member]
Other Postretirement Benefit Plans Defined Benefit [Member]
Postretirement Plans [Member]
Amortization of: [Abstract]
Service cost
Interest cost
Expected return on plan assets
Prior service costs/(credits)
Curtailments and settlements - net
Net periodic benefit costs
Pension and Postretirement Benefit Plans Narrative [Abstract]
Contributions
Expected contributions in next fiscal year
Special termination benefits
Schedule Of Earnings Per Share Basic By Common Class And Schedule Of Earnings Per Share Diluted By Common Class [Text Block]
Income Loss From Continuing Operations Available To Common Stockholders Basic
Net periodic benefit costs
Total indefinite-lived intangible assets
Income from continuing operations attributable to Pfizer Inc. common shareholders
Income from continuing operations attributable to Pfizer Inc. common shareholders
Less: Preferred stock dividends - net of tax
Net income attributable to Pfizer Inc. common shareholders
Net income attributable to Pfizer Inc. common shareholders
Weighted - average number of common shares outstanding
EPS Numerator - Basic:
EPS Numerator - Diluted:
EPS Denominator - Diluted:
Common share equivalents: stock options, stock issuable under employee compensation plans and convertible preferred stock
Weighted - average number of common shares outstanding and common share equivalents
Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans
EPS Denominator - Basic:
Eps Denominator Basic Abstract
Eps Numerator Diluted Abstract
Eps Denominator Diluted Abstract
Effective tax rate
Tax benefits for resolution of certain tax positions
Schedule of Segment Reporting Information by Segment [Text Block]
Schedule of Revenue by Products [Text Block]
Revenues SI
Segment Reporting Information by Segment [Axis]
Reporting Segment [Domain]
Corporate / Other [Member]
The charge against earnings resulting from the write-off of the deferred tax asset related to the Medicare Part D subsidy for retiree prescription drug coverage, resulting from changes in the U.S. healthcare legislation enacted in March 2010 concerning the tax treatment of that subsidy effective for tax years beginning after December 31, 2012.
Segment Revenues and Profit Loss [Abstract]
Segment profit / loss
Segment Revenues and Profit Loss Narrative [Abstract]
Segment profit/loss
Purchase Accounting Significant Impacts
Purchase accounting for acquisitions
Significant impacts of purchase accounting for acquisitions, including intangible asset amortization and charges related to fair value adjustments.
Biopharmaceutical consists of the Primary Care, Specialty Care, Oncology, Established Products and Emerging Markets customer-focused units and includes products that prevent and treat cardiovascular and metabolic diseases, central nervous system disorders, arthritis and pain, infectious and respiratory diseases, urogenital conditions, cancer, eye diseases and endocrine disorders, among others. Biopharmaceutical segment profit includes costs related to research and development, manufacturing, and sales and marketing activities that are associated with the products in our Biopharmaceutical segment.
Diversified includes Animal Health products that prevent and treat diseases in livestock and companion animals, including vaccines, parasiticides and anti-infectives; Consumer Healthcare products that include over-the-counter healthcare products such as pain management therapies (analgesics and heat wraps), cough/cold/allergy remedies, dietary supplements, hemorrhoidal care and personal care items; Nutrition products such as infant and toddler nutritional products; and Capsugel, which represents our capsule products and services business. Diversified segment profit includes costs related to research and development, manufacturing, and sales and marketing activities that are associated with the products in our Diversified segment.
Certain costs, such as significant impacts of purchase accounting for acquisitions, restructuring and acquisition-related costs and costs related to our cost-reduction initiatives.
This element represents the income or loss from continuing operations available to common stockholders which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items and cumulative effects of changes in accounting principles, but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests and preferred stock dividends declared or paid in the period, if any.
Net Interest Income Expense
Net interest expense/(income)
Acquisition Related Costs
Acquisition - related costs
Products [Domain]
Animal Health [Member]
Consumer Healthcare [Member]
Nutrition [Member]
Capsugel [Member]
Lipitor [Member]
Enbrel [Member]
Lyrica [Member]
Effexor [Member]
Celebrex [Member]
Prevnar / Prevenar 7 [Member]
Viagra [Member]
Xalatan / Xalacom [Member]
Norvasc [Member]
Zyvox [Member]
Prevnar / Prevenar 13 [Member]
Zosyn / Tazocin [Member]
Detrol / Detrol LA [Member]
Sutent [Member]
Premarin family [Member]
Geodon / Zeldox [Member]
Genotropin [Member]
Chantix / Champix [Member]
Vfend [Member]
BeneFIX [Member]
Caduet [Member]
Aricept [Member]
Zithromax / Zmax [Member]
ReFacto / Xyntha [Member]
All other [Member]
Alliance revenues [Member]
Aromasin [Member]
Zoloft [Member]
Revatio [Member]
Medrol [Member]
Cardura [Member]
Deferred Tax Asset Writeoff
Significant product revenues
Revenues
Revenues by geographic area [Line Items]
Significant product revenues are as follows:
Entity - Wide Disclosure on Geographic Areas, Revenue from External Customers Attributed to Individual Foreign Countries [Axis]
Segment, Geographical [Domain]
Revenue by geographic area - United States
Revenue by geographic area - Foreign Countries
The percentage change in revenue attributed to foreign countries.
Total Revenues
Net tax accounts
Implementation costs [Member]
Restructuring Accrual [Member]
Intangible assets, gross carrying amount
Expected return on plan assets
Special termination benefits
Percentage Change in Revenue - Foreign Countries
Percentage Change In Revenue - United States
Percentage Change In Revenue
The gross carrying amount of all identifiable intangible assets for the period ended.
The percentage change in revenue attributed to the entity's country of domicile.
The percentage change in revenue.
Total selected financial assets at the balance sheet date.
Total selected financial liabilities.
Total selected financial assets
Total selected financial liabilities
Transaction costs representing external costs directly related to a business combination and integration cots representing external, incremental costs directly related to integrating acquired operations.
Amount of net interest income and expense.
Restructuring charges and implementation costs associated with Pfizer's cost-reduction initiatives.
Total debt securities maturities
This item represents debt securities which are expected to mature within one year of the balance sheet date.
This item represents debt securities which are expected to mature after one year and through five years from the balance sheet date.
Total other financial liabilities
Item represents the expected reduction of the workforce due to cost-reduction initiatives.
Item represents the number of employees terminated due to cost-reduction initiatives.
The excess of the consideration transferred for Wyeth over the fair value of acquired net assets recognized as of the acquisition date.
This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to the net amount recognized as of the acquisition date for the aggregate identifiable assets acquired in excess of or less than the aggregate liabilities assumed.
This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to the net amount recognized as of the acquisition date for the aggregate assets, including goodwill, in excess of or less than the aggregate liabilities assumed. This amount may also be viewed as the measurement period adjustment to the incremental amount of equity that the consolidated entity (including the portion attributable to the noncontrolling interest) will recognize as a result of the business combination.
Less: Amounts attributable to noncontrolling interests
Current deferred tax liabilities and other current liabilities
Other noncurrent liabilities
Cost Reduction Initiatives and Acquisition Costs of Wyeth
Footnote information
Additional depreciation - asset restructuring and implementation costs
Restructuring charges footnote information
Restructuring charges narrative
Restructuring charges narrative [Abstract]
Restructuring charges
Current deferred tax liabilities and other current liabilities
Other noncurrent liabilities
Financial Assets Measured At Fair Value On Recurring Basis
Other selected financial assets
Financial Liabilities Measured At Fair Value On Recurring Basis
Other financial liabilities
Footnotes to selected financial assets and liabilities
Selected financial assets and liabilities presented in the condensed consolidated balance sheets
Liabilities
Footnotes to selected financial assets and liabilities presented in consolidated balance sheets
Short - Term Borrowings
Long - Term Debt
Guarantee
Investments in Debt and Equity Securities
Gains / (losses) incurred to hedge or offset operational foreign exchange or interest rate risk
Non - Derivative Financial Instruments in Net Investment Hedge Relationships
Financial Instruments Narrative
Goodwill and Other Intangible Assets Narrative
Restructuring and acquisition - related costs
Amortization of:
Pension and Postretirement Benefit Plans Narrative
Segment Revenues and Profit Loss
Segment Revenues and Profit Loss Narrative
Debt securities maturities within 1 year
Goodwill [Line Items]
Revenues
Total other comprehensive loss
Total other comprehensive income/(loss)
Amounts Recognized as of Acquisition Date (as previously reported) [Member]
Measurement Period Adjustments [Member]
Amounts Recognized as of Acquisition Date, As Adjusted [Domain]
Measurement Period Adjustments
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangibles Excluding In Process Research And Development
The amount of identifiable intangible assets excluding in process research and development recognized as of the acquisition date.
Identifiable intangible assets, excluding in-process research and development
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Long Term Debt
The amount of long term debt recognized as of the acquisition date.
Long-term debt
Business Combination Provisional Information Initial Accounting Incomplete Adjustment Identifiable Intangible Assets Excluding In Process Research And Development
This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to identifiable intangible assets excluding in process research and development in connection with a business combination for which the initial accounting was incomplete.
Identifiable intangible assets, excluding in-process research and development
Business Combination Acquisition Related Costs Transaction Costs
This element represents external costs directly related to effecting a business combination which costs have been expensed during the period. Such costs include advisory, legal, accounting, valuation, and other similar services.
Transaction costs
Goodwill Purchase Price Adjustments
Reflects net changes to the recorded value of goodwill not yet allocated to reportable segments for purchase accounting adjustments needed to revise the carrying amount of goodwill to fair value.
Additions
Actuarial losses
Total profit
Total revenues
Actuarial losses
Deferred tax assets write - off
Wyeth [Member]
Business Acquisition [Axis]
Business Acquisition Acquiree [Domain]
Net income attributable to Pfizer Inc. common shareholders EPS
Net income attributable to Pfizer Inc. common shareholders
Revenues
Goodwill [Table]
Schedule of Inventories [Table]
Inventories [Table]
Schedule of Indefinite-lived and Finite-lived Intangible Assets [Table]
Schedule of Defined Benefit Plans Disclosures [Table]
Defined Benefit Plan Disclosure [Line Items]
Schedule of Earnings Per Share Basic and Diluted by Common Class [Table]
Schedule of Segment Reporting Information by Segment [Table]
Segment Reporting Information [Line Items]
Entity-Wide Disclosure on Geographic Areas, Revenue from External Customers Attributed to Individual Foreign Countris
Schedule of Available for sale Securities and Held to maturity Securities [Table]
Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table]
Schedule of Comprehensive Income (Loss) [Table]
Schedule of Restructuring Charges [Table]
Restructuring Charges [Line Items]
Income Taxes [Line Items]
Income Taxes [Table]
Derivative Instruments Gain (Loss) [Line Items]
Schedule of Available for sale Securities and Held to maturity Securities [Line Items]
Inventories Line items
Schedule of Earnings Per Share Basic and Diluted [Line Items]
Schedule of Comprehensive Income [Line Items]
Business Combination Provisional Information Initial Accounting Incomplete Adjustment Working Capital Excluding Inventories
Working capital, excluding inventories
This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to working capital excluding inventories in connection with a business combination for which the initial accounting was incomplete.
Business Combination Provisional Information Initial Accounting Incomplete Adjustment Other Noncurrent Assets
Other noncurrent assets
This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to other noncurrent assets in connection with a business combination for which the initial accounting was incomplete.
Business Combination Provisional Information Initial Accounting Incomplete Adjustment Long Term Debt
Long-term debt
This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to long term debt in connection with a business combination for which the initial accounting was incomplete.
Business Combination Provisional Information Initial Accounting Incomplete Adjustment Benefit Obligations
Benefit obligations
This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to benefit obligations in connection with a business combination for which the initial accounting was incomplete.
Business Combination Provisional Information Initial Accounting Incomplete Adjustment Other Noncurrent Liabilities
Other noncurrent liabilities
This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to other noncurrent liabilities in connection with a business combination for which the initial accounting was incomplete.
Business Combination Provisional Information Initial Accounting Incomplete Adjustment Business Combination Acquisition Of Less Than 100 Percent Noncontrolling Interest Fair Value
Less: Amounts attributable to noncontrolling interests
This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to the fair value of the noncontrolling interest in the acquiree at the acquisition date.
Total consideration transferred Measurement Period
Total consideration transferred
Schedule Of Cost Reduction Initiatives And Acquisition Related Costs Text Block
Schedule of costs in connection with cost-reduction initiatives and the Wyeth acquisition [Text Block]
represents the impact in the statement of income of changes in the estimated useful lives of assets involved in restructuring actions.
Schedule Of Additional Depreciation Asset Restructuring Text Block
Schedule of additional depreciation from asset restructuring [Text Block]
Unused Bridge Loan
Short-Term financing agreement entered into with certain financial institutions to partially fund the acquisition of Wyeth. Pfizer did not incur any borrowings under the bridge term loan credit agreement and it was terminated in June 2009.
Schedule of identifiable intangible assets [Text Block]
Goodwill Acquired During Period
Additions
Selected Financial Assets And Liabilities Text Block
Information about certain financial assets and liabiltiies [Text Block]
Selected Financial Assets And Liabilities By Balance Sheet Grouping [Text Block]
This item represents the locations of selected financial assets and liabilities by balance sheet grouping at the balance sheet date.
Selected financial ssets and liabilities presented in the condensed consolidated balance sheets [Text Block]
This item represents investments in debt securities which are categorized neither as held-to-maturity nor trading. Such securities are reported at fair value, with unrealized gains and losses excluded from earnings and reported in a separate component of shareholders' equity (other comprehensive income), unless the security is determined to have had an other than temporary decline in fair value below its amortized cost basis. All or a portion of the unrealized holding gain or loss of an Available-for-sale Security shall be recognized in earnings during the period of the hedge, for other than temporary declines in fair value below cost basis.
This item represents equity securities categorized neither as held-to-maturity nor trading. Money market funds represent ownership in debt instruments. If money markets funds are determined to have had an other than temporary decline in fair value below its amortized cost basis the loss loss shall be recognized in earnings.
This item represents equity securities excluding money market funds categorized neither as held-to-maturity nor trading. Equity securities excluding money market funds represent ownership interests or the right to acquire ownership interests in corporations and other legal entities which ownership interest is represented by shares of common or preferred stock (which is not mandatorily redeemable or redeemable at the option of the holder), convertible securities, stock rights, or stock warrants. Unrealized gains and losses related to Available-for-sale Securities are excluded from earnings and reported in a separate component of shareholders' equity (other comprehensive income), unless the Available-for-sale Security is designated as a hedge or is determined to have had an other than temporary decline in fair value below its amortized cost basis. All or a portion of the unrealized holding gain or loss of an Available-for-sale Security that is designated as being hedged in a fair value hedge shall be recognized in earnings during the period of the hedge, as should other than temporary declines in fair value below costs basis.
This category includes information about debt securities (such as bonds) issued by political subdivisions.
The carrying value of securities purchased to be resold in reverse repurchase transactions.
Held To Maturity Securities Debt Maturities Net Carrying Amount
Held - to - maturity debt securities, carried at amortized cost
Instruments used as offsets (assets)
Instruments used as offsets (liabilities)
Selected Financial Assets Cash And Cash Equivalents
Cash and cash equivalents
Selected Financial Assets Long Term Investments And Loans
Long-term investments and loans
Selected Financial Assets Current Deferred Tax Assets And Other Current Assets
Current deferred tax assets and other current assets
Selected Financial Assets Noncurrent Deferred Tax Assets And Other Noncurrent Assets
Noncurrent deferred tax assets and other noncurrent assets
Selected financial assets presented in the balance sheet caption, Cash and cash equivalents, at the balance sheet date.
Selected financial assets presented in the balance sheet caption, Long-term investments and loans, at the balance sheet date.
Selected financial assets presented in the balance sheet caption, Current deferred tax assets and other current assets, at the balance sheet date.
Selected financial assets presented in the balance sheet caption, Noncurrent deferred tax assets and other noncurrent assets, at the balance sheet date.
Other asset backed securities [Member]
Held-to-maturity Securities, Debt Maturities, within One Year, Net Carrying Amount
Held - to - maturity debt securities maturities within 1 year
Held-to-maturity Securities, Debt Maturities, after One Through Five Years, Net Carrying Amount
Held - to - maturity debt securities with maturities over 1 to 5 years
Held - to - maturity debt securities maturities total
Marketable Securities
Total
Aggregate notional amount of foreign currency derivative financial instruments
Derivative Instruments, Gain (Loss) by Income Statement Location [Axis]
Income Statement and Other Comprehensive Income Location [Domain]
Other Comprehensive Income [Member]
Other Income Expense [Member]
US Treasury interest rate locks [Member]
Non Derivative Financial Instruments In Net Investment Hedge Relationships Gain Loss Recognized In Other Comprehensive Income Effective Portion Net
Non Derivative Financial Instruments In Net Investment Hedge Relationships Gain Loss Recognized In Income Net
Recognized in OCI
Recognized in OID
Aggregate fair value of net derivative liabilities
Concentration risk maximum exposure
Securities received as collateral
Total
Total
This category includes information about debt securities (such as bonds) that are issued by a either a domestic or foreign national government.
Asset write-offs and impairment charges
Purchases of common stock
Purchases of common stock
Amounts Recognized as of Acquisition Date (as adjusted) [Member]
Long-term Debt, Type [Axis]
Long-term Debt, Type [Domain]
Senior Debt Obligations [Member]
Schedule Of Defined Benefit Plan Net Periodic Benefit Costs Text Block
Schedule Of Defined Benefit Plan Net Periodic Benefit Costs Text Block.
Indefinite-lived intangible assets footnote Abstract
Indefinite-lived intangible assets footnote
Impairment charge
Impairment Of Intangible Assets Indefinite lived Excluding Goodwill After Tax
Impairment charge (after-tax)
The amount of impairment loss after tax recognized in the period resulting from the write-down of the carrying amount of an indefinite-lived intangible asset, other than goodwill, to fair value.
Goodwill not allocated [Member]
Schedule of Finite Lived And Indefinite Lived Intangible Assets By Major Class Text Block
Schedule Of Earnings Per Share Basic By Common Class And Schedule Of Earnings Per Share Diluted By Common Class Text Block.
Cost reduction initiatives
Restructuring charges and implementation costs
Pristiq [Member]
Developed Europe [Member]
Developed Rest Of World [Member]
Emerging Markets [Member]
Gain (loss) net recorded in income from non-derivative financial instruments in net investment hedge relationships.
Gain (loss) net recorded in other comprehensive income from non-derivative financial instruments in net investment hedge relationships.
Private Equity Securities Owned Carried At Cost Or Equity
Private equity securities, carried at cost or equity method
This item represents the carrying amount on the entity's balance sheet of its investment in private equity securities accounted for under the cost and equity methods. The carrying amount for equity method investees is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment losses recognized. The original cost of the cost method investments may differ from the aggregate carrying amount due to various adjustments such as: (i) dividends received in excess of earnings after the date of investment that are considered a return of investment and therefore recorded as reductions to cost of the investment, or (ii) a series of operating losses of an investee or other factors which may indicate that a decrease in value of the investment has occurred which is other than temporary and should accordingly be recognized.
Fair value of long term foreign currency debt which is used as a hedging instrument.
Fair value of short term foreign currency borrowings which are used as hedging instruments.
Long Term Debt Fair Value
Fair value of long term debt
US Corporate Debt Guaranteed By Federal Deposit Insurance Corporation [Member]
This category includes information about debt securities issued by a domestic corporate business entity, which are guaranteed by the Federal Deposit Insurance Corporation.
Trading Securities Held In Trust
Trading securities
Trading securities consists of securities that are bought and held principally for the purpose of selling them in the near term (thus held for only a short period of time). Generally, trading generally reflects active and frequent buying and selling, and trading securities are generally used with the objective of generating profits on short-term differences in price.
Estimated fair value of long term debt at the balance-sheet date.
Goodwill recognized as of the Acquisition Date (as adjusted)
Allocation of Other Goodwill
Inventories
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Period Increase Decrease
Currency translation adjustment and other
Schedule of Comprehensive Income
Indefinite-lived intangible assets brands
Indefinite-lived intangible assets in-process research and development
Indefinite-lived intangible assets trademarks
Short-term loans, carried at cost
Maturing in 2038 [Member]
Schedule of Revenues by Geographic Area [Text Block]
Schedule of revenues by geographic area.
Schedule of components of inventories.
Tax benefits for resolution of certain tax positions